Brief: Karyopharm Therapeutics Q1 Net Income USD -23.462 Million
12/05/2025 21:05
May 12 (Reuters) - Karyopharm Therapeutics Q1 product revenue USD 21.054 million. Q1 operating expenses USD 63.271 million Q1 operating income USD -33.256 million outlook FY revenue USD 140-155 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview